The role of V2 vasopressin antagonists in hyponatremia

Cardiovascular Research

Volumn 51, Issue 3, 2001, Pages 403-408

  Palm, Catrin ^a   Reimann, Doreen ^a   Gross, Peter ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Nephrology MK III   (Germany)

Author keywords

Hormones; Intra extracellular ions

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 7 CHLORO 5 HYDROXY 1 [2 METHYL 4 (2 METHYLBENZOYLAMINO)BENZOYL] 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPINE; BENZAZEPINE DERIVATIVE; CONIVAPTAN; DEMECLOCYCLINE; LITHIUM CARBONATE; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST; VPA 343;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DRUG EFFECT; DRUG EFFICACY; FLUID INTAKE; HEMODYNAMICS; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SODIUM BLOOD LEVEL;

ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; LIVER CIRRHOSIS; RECEPTORS, VASOPRESSIN;

EID: 0035882341     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00288-7     Document Type: Review

References (47)

1. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, non-peptide AVP V2-receptor antagonist
2. Characterization of SR 121463A, a highly potent selective, orally active vasopressin V2-receptor antagonist
3. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4] benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA 985): An orally active arginine vasopressin antagonist with selectivity for V2 receptors
4. OPC-41061, a highly potent human vasopressin V2-receptor antagonist-pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
5. Pharmacological profile of VPA-343, a novel selective vasopressin V2 receptor antagonist, in rats
6. Characterization of VPA 985 as a specific, nonpeptide vasopressin V2 antagonist
7. Pathogenesis of sodium and water in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy
8. Pathogenesis of sodium and water in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy
9. Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients
10. Radioimmunoassay of arginine vasopressin in hyponatremic patients with congestive heart failure
11. Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
12. Effect of AVP antagonist on water excretion in inferior vena cava constriction
13. Disturbed volume homeostasis in patients with cirrhosis of the liver
14. Role of vasopressin in abnormal water excretion in cirrhotic patients
15. Vascular effects of arginine vasopressin during fluid deprivation in rat
16. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats
17. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormon (SIADH)
18. Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion
19. Modulation of plasma and platelet AVP by cardiac function in patients with heart failure
20. Cellular and subcellular immunolocalization of vasopressin regulated water channel in rat kidney
21. Effects of DDAVP and AVP on sodium and water balance in conscious rat
22. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone
23. On the mechanism of lithium-induced diabetes insipidus in man and rat
24. Treatment of the syndrome of antidiuretic hormone with lithium carbonate
25. Discovery, development, and some uses of vasopressin and oxytocin antagonists
26. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone
27. Species heterogeneity and antidiuretic hormone antagonists: What are the predictors
28. Pharmacological profile of YM 087, a novel non-peptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo
29. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
30. Enhancement of vascular action of arginine vasopressin by diminishing extracellular sodium concentration
31. Functional significance of cell volume regulatory mechanisms
32. Selective V2 receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure
33. Effects of an oral nonpeptide, selective V2 receptor vasopressin antagonist in human heart failure
34. Pharmacotherapy for hyponatremia in heart failure: Effects of a new combined V1A/V2 vasopressin receptor antagonist, conivaptan (YM087) administered orally
35. Treatment of hyponatremia in patients with SIADH or CHF with intravenous conivaptan (YM 087), a new combined vasopressin V1A/V2 receptor antagonist
36. Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA Class III/IV heart failure
37. Hemodynamic effects of conivaptan hydrochloride (YM 087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure
38. Aquaretic effects of the nonpeptide V2 antagonist OPC 31260 in hydropenic humans
39. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in man
40. Beneficial effects of V2-vasopressin antagonist (ANTAG) in the hyponatremia of clinical cardiac failure (CHF), SIADH and liver cirrhosis (CI)
41. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats
42. Therapeutic and diagnostic potential of a vasopressinV-2 antagonist for impaired water handling in cirrhosis
43. VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis-a double blind placebo controlled multicenter trial
44. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP
45. V2 receptor antagonism of dDAVP-induced release of hemostasis factors in conscious dogs
46. Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist VPA 985